Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitsuru Hashiramoto

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Molecular Endocrinology (Baltimore, Md.)|November 24, 2011
Ablation of 3-phosphoinositide-dependent protein kinase 1 (PDK1) in vascular endothelial cells enhances insulin sensitivity by reducing visceral fat and suppressing angiogenesisKazuhito Tawaramoto, Ko Kotani, Mitsuru Hashiramoto, et al.
Diabetes Research and Clinical Practice|May 29, 2013
Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitusFuminori Tatsumi, Mitsuru Hashiramoto, Hidenori Hirukawa, et al.
Endocrine Journal|June 16, 2015
Anti-hypertensive azelnidipine preserves insulin signaling and glucose uptake against oxidative stress in 3T3-L1 adipocytesFuminori Tatsumi, Hideaki Kaneto, Mitsuru Hashiramoto, et al.
American Journal of Human Genetics|September 1, 2004
The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3Haruhiko Osawa, Kazuya Yamada, Hiroshi Onuma, et al.
Endocrine Journal|September 10, 2009
A pilot study suggests that the G/G genotype of resistin single nucleotide polymorphism at -420 may be an independent predictor of a reduction in fasting plasma glucose and insulin resistance by pioglitazone in type 2 diabetesHideichi Makino, Ikki Shimizu, Satoshi Murao, et al.
Journal of Diabetes Investigation|May 21, 2014
International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program valuesAtsunori Kashiwagi, Masato Kasuga, Eiichi Araki, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Molecular Endocrinology (Baltimore, Md.)|November 24, 2011
Ablation of 3-phosphoinositide-dependent protein kinase 1 (PDK1) in vascular endothelial cells enhances insulin sensitivity by reducing visceral fat and suppressing angiogenesisKazuhito Tawaramoto, Ko Kotani, Mitsuru Hashiramoto, et al.
Diabetes Research and Clinical Practice|May 29, 2013
Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitusFuminori Tatsumi, Mitsuru Hashiramoto, Hidenori Hirukawa, et al.
Endocrine Journal|June 16, 2015
Anti-hypertensive azelnidipine preserves insulin signaling and glucose uptake against oxidative stress in 3T3-L1 adipocytesFuminori Tatsumi, Hideaki Kaneto, Mitsuru Hashiramoto, et al.
American Journal of Human Genetics|September 1, 2004
The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3Haruhiko Osawa, Kazuya Yamada, Hiroshi Onuma, et al.
Endocrine Journal|September 10, 2009
A pilot study suggests that the G/G genotype of resistin single nucleotide polymorphism at -420 may be an independent predictor of a reduction in fasting plasma glucose and insulin resistance by pioglitazone in type 2 diabetesHideichi Makino, Ikki Shimizu, Satoshi Murao, et al.
Journal of Diabetes Investigation|May 21, 2014
International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program valuesAtsunori Kashiwagi, Masato Kasuga, Eiichi Araki, et al.
Pageof 3